0001832352--12-312021Q200178333228750002875000P10D00.50178333228750002875000false000001832352cahcu:PrivatePlacementWarrantsMembercahcu:SponsorMember2021-01-012021-06-300001832352us-gaap:RetainedEarningsMember2021-06-300001832352us-gaap:AdditionalPaidInCapitalMember2021-06-300001832352us-gaap:RetainedEarningsMember2021-03-310001832352us-gaap:AdditionalPaidInCapitalMember2021-03-3100018323522021-03-310001832352us-gaap:RetainedEarningsMember2020-12-310001832352us-gaap:AdditionalPaidInCapitalMember2020-12-310001832352us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001832352us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001832352us-gaap:OverAllotmentOptionMember2021-01-290001832352us-gaap:CommonClassBMember2021-03-310001832352cahcu:CommonClassaSubjectToRedemptionMember2021-03-310001832352cahcu:UnsecuredPromissoryNoteMembercahcu:FounderSharesMembercahcu:SponsorMember2021-01-292021-01-290001832352cahcu:PromissoryNoteWithRelatedPartyMember2021-01-292021-01-290001832352cahcu:SponsorMemberus-gaap:PrivatePlacementMember2021-01-292021-01-290001832352cahcu:PromissoryNoteWithRelatedPartyMember2021-06-300001832352us-gaap:WarrantMember2021-06-300001832352us-gaap:WarrantMember2021-03-310001832352cahcu:PublicWarrantsMember2021-03-310001832352cahcu:PrivatePlacementWarrantsMember2021-03-310001832352us-gaap:WarrantMember2021-01-292021-01-290001832352cahcu:PublicWarrantsMember2021-01-292021-01-290001832352cahcu:PrivatePlacementWarrantsMember2021-01-292021-01-290001832352us-gaap:WarrantMember2021-04-012021-06-300001832352cahcu:PublicWarrantsMember2021-04-012021-06-300001832352cahcu:PrivatePlacementWarrantsMember2021-04-012021-06-300001832352us-gaap:WarrantMember2021-01-012021-03-310001832352cahcu:PublicWarrantsMember2021-01-012021-03-310001832352cahcu:PrivatePlacementWarrantsMember2021-01-012021-03-310001832352us-gaap:FairValueInputsLevel1Member2021-04-012021-06-300001832352us-gaap:FairValueInputsLevel1Member2021-01-012021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2021-03-310001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-03-310001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001832352cahcu:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2021-01-290001832352cahcu:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-01-290001832352cahcu:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-01-290001832352cahcu:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-01-290001832352cahcu:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2021-01-290001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2021-01-290001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-01-290001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-01-290001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2021-01-290001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2021-01-290001832352us-gaap:CommonClassAMember2021-06-300001832352srt:ScenarioPreviouslyReportedMemberus-gaap:CommonClassBMember2021-01-290001832352srt:ScenarioPreviouslyReportedMemberus-gaap:CommonClassAMember2021-01-290001832352srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberus-gaap:CommonClassAMember2021-01-290001832352us-gaap:CommonClassAMember2020-12-310001832352cahcu:CommonClassaSubjectToRedemptionMember2021-06-300001832352us-gaap:CommonClassBMember2021-01-290001832352us-gaap:CommonClassAMember2021-01-290001832352cahcu:CommonClassaSubjectToRedemptionMember2021-01-290001832352us-gaap:CommonClassBMember2020-12-310001832352cahcu:CommonClassaSubjectToRedemptionMember2020-12-310001832352cahcu:CommonClassaNotSubjectToRedemptionMember2020-12-310001832352cahcu:PrivatePlacementWarrantsMember2021-06-300001832352cahcu:SponsorMemberus-gaap:PrivatePlacementMember2021-01-290001832352cahcu:PublicWarrantsMember2021-06-300001832352cahcu:PublicWarrantsMemberus-gaap:IPOMember2021-01-290001832352us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-06-300001832352srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-01-290001832352us-gaap:CommonClassAMember2021-01-012021-06-300001832352cahcu:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember2021-01-012021-06-300001832352cahcu:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneHalfOfOneWarrantMember2021-01-012021-06-300001832352us-gaap:CommonClassBMember2021-08-020001832352us-gaap:CommonClassAMember2021-08-020001832352us-gaap:OverAllotmentOptionMember2021-01-292021-01-290001832352us-gaap:IPOMember2021-01-292021-01-290001832352cahcu:FounderSharesMember2021-01-012021-06-300001832352us-gaap:IPOMember2021-01-012021-06-300001832352cahcu:FounderSharesMembercahcu:SponsorMemberus-gaap:CommonClassBMember2020-10-282020-10-280001832352cahcu:PrivatePlacementWarrantsMember2021-01-012021-06-3000018323522020-12-312020-12-310001832352cahcu:FounderSharesMembercahcu:SponsorMemberus-gaap:CommonClassBMember2020-10-280001832352cahcu:FounderSharesMembercahcu:SponsorMemberus-gaap:CommonClassBMember2021-01-292021-01-290001832352cahcu:PublicWarrantsMemberus-gaap:IPOMember2021-01-292021-01-290001832352cahcu:RelatedPartyLoansMember2021-06-300001832352cahcu:PromissoryNoteWithRelatedPartyMember2020-10-2800018323522020-12-310001832352cahcu:DueToRelatedPartyMembercahcu:SponsorMember2021-01-012021-06-300001832352us-gaap:IPOMember2021-01-290001832352srt:ScenarioPreviouslyReportedMember2021-01-2900018323522021-01-290001832352us-gaap:CommonClassBMember2021-01-012021-06-3000018323522021-06-3000018323522020-10-072020-10-070001832352us-gaap:CommonClassBMember2021-06-300001832352cahcu:CommonClassaNotSubjectToRedemptionMember2021-06-300001832352cahcu:WorkingCapitalLoansWarrantMembercahcu:RelatedPartyLoansMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMemberus-gaap:CommonClassAMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMembercahcu:SponsorMember2021-06-300001832352cahcu:PrivatePlacementWarrantsMembercahcu:RelatedPartyLoansMember2021-06-300001832352cahcu:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceedsEighteenPointZeroMembercahcu:PublicWarrantsMember2021-01-012021-06-300001832352cahcu:PublicWarrantsMember2021-01-012021-06-300001832352us-gaap:RetainedEarningsMember2021-04-012021-06-300001832352us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000018323522021-04-012021-06-300001832352us-gaap:RetainedEarningsMember2021-01-012021-03-310001832352us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018323522021-01-012021-03-310001832352cahcu:CommonClassaSubjectToRedemptionMember2021-01-012021-03-310001832352cahcu:CommonClassaSubjectToRedemptionMember2021-04-012021-06-300001832352cahcu:CommonClassaSubjectToRedemptionMember2021-01-012021-06-3000018323522021-01-012021-06-30iso4217:USDxbrli:purexbrli:sharesiso4217:USDxbrli:sharescahcu:Votecahcu:securitycahcu:Dcahcu:Y

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~June 3130, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

CA Healthcare Acquisition Corp.

(Exact name of registrant as specified in its charter)


Delaware	001-39947	85-3469820
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)



99 Summer Street, Suite 200
Boston, Massachusetts		02110
(Address of principal executive offices)		(Zip Code)

(617) 314-3901

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Class A Common Stock and one-half of one Warrant	CAHCU	The Nasdaq Stock Market LLC
Class A Common Stock, par value $0.0001 per share	CAHC	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share	CAHCW	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share, subject to adjustment	CAHCW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧☒ No ◻☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧☒ No ◻☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻☐ Accelerated filer ◻☐ Non-accelerated filer ⌧☒ Smaller reporting company ⌧☒ Emerging growth company ⌧☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ⌧☒ No ◻☐

AsTable of ~~May 24, 2021, 11,500,000 Class A common stock, par value $0.0001, and 2,875,000 Class B common stock, par value $0.0001, were issued and outstanding.~~Contents

As of August 2, 2021, 11,500,000 shares of Class A common stock, par value $0.0001 per share, and 2,875,000 shares of Class B common stock, par value $0.0001 per share, were issued and outstanding.

Table of Contents

CA HEALTHCARE ACQUISITION CORP.

Quarterly Report on Form 10-Q

Table of Contents


		Page No.

PART I. FINANCIAL INFORMATION

Item 1.	Condensed Financial Statements	1

	~~Unaudited~~ Condensed Balance Sheets as of ~~March~~June 3130, 2021 (Unaudited) and December 31, 2020	1

	Unaudited Condensed ~~Statement~~Statements of Operations for the ~~period~~three ~~from~~and ~~January~~six 1,months ~~2021~~ended ~~through~~June ~~March 31~~30, 2021	2

	Unaudited Condensed ~~Statement~~Statements of Changes in Stockholders’ Equity for ~~the~~three ~~period~~and ~~from~~six ~~January~~months 1,ended ~~2021~~June ~~through March 31~~30, 2021	3

	Unaudited Condensed Statement of Cash Flows for ~~the~~six ~~period~~months ~~from~~ended ~~January~~June 130, 2021 ~~through March 31, 2021~~	4

	Notes to Unaudited Condensed Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2021

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2425

Item 4.	Controls and Procedures	2425

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	2526

Item 1A.	Risk Factors	2526

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities	2527

Item 3.	Defaults Upon Senior Securities	2627

Item 4.	Mine Safety Disclosures	2627

Item 5.	Other Information	2627

Item 6.	Exhibits	2628

SIGNATURES

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Condensed Financial Statements.

CA HEALTHCARE ACQUISITION CORP.

~~UNAUDITED~~ CONDENSED BALANCE SHEETS


	~~March~~June 3130, 2021		December 31, 2020
	(Unaudited)
Assets:
Current assets:
Cash	$	~~847~~623,~~122~~676	$	9,498
Prepaid expenses		~~394~~328,~~984~~863		—
Total current assets		1952,~~242,106~~539		9,498
Investments held in Trust Account		115,~~009~~012,~~648~~434		—
Deferred offering costs associated with initial public offering		—		141,200
Total Assets	$	~~116~~115,~~251~~964,~~754~~973	$	150,698

Liabilities and Stockholders' Equity:
Current liabilities:
Accounts payable	$	1223,~~875~~750	$	8,000
Accrued expenses		95110,~~000~~288		—
Franchise tax payable		49,~~426~~971		609
Due to related party		2,275		—
Note payable - related party		—		119,352
Total current liabilities		~~159~~186,~~576~~284		127,961
Deferred underwriting commissions		4,025,000		—
Derivative warrant liabilities		69,~~530~~587,~~500~~000		—
Total liabilities		1013,~~715~~798,~~076~~284		127,961

Commitments and Contingencies

Class A common stock, $0.0001 par value; 10,053,667 and -0- shares subject to possible redemption at $10.00 per share as of March 31, 2021 and December 31, 2020, respectively		100,536,670		—
Class A common stock, $0.0001 par value; 9,716,668 and -0- shares subject to possible redemption at $10.00 per share as of June 30, 2021 and December 31, 2020, respectively		97,166,680		—

Stockholders' Equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of March 31, 2021 and December 31, 2020		—		—
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of June 30, 2021 and December 31, 2020		—		—
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 1,446,333 and -0- shares issued and outstanding (excluding 10,053,667 and -0- shares subject to possible redemption) as of March 31, 2021 and December 31, 2020, respectively		145		—
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 1,783,332 and -0- shares issued and outstanding (excluding 9,716,668 and -0- shares subject to possible redemption) as of June 30, 2021 and December 31, 2020, respectively		178		—
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 2,875,000 shares issued and outstanding as of March 31, 2021 and December 31, 2020		288		288
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 2,875,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020		288		288
Additional paid-in capital		25,~~218~~588,~~505~~462		24,712
Retained earnings (accumulated deficit)		2,781,070		(2,263)
Accumulated deficit		(588,919)		(2,263)
Total stockholders' equity		5,000,~~008~~009		22,737
Total Liabilities and Stockholders' Equity	$	~~116~~115,~~251~~964,~~754~~973	$	150,698

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

CA HEALTHCARE ACQUISITION CORP.

UNAUDITED CONDENSED ~~STATEMENT~~STATEMENTS OF OPERATIONS

~~FOR THE THREE MONTHS ENDED MARCH 31, 2021~~


	For the three months		For the six months ended
	ended June 30, 2021		June 30, 2021
General and administrative expenses	$	266,412	$	410,300
Franchise tax expense		49,863		98,680
Loss from operations		(316,275)		(508,980)
Other income (expense)
Change in fair value of derivative warrant liabilities		(3,056,500)		270,500
Offering costs - derivative warrant liabilities		—		(360,610)
Income from investments held in Trust Account		2,786		12,434
Loss before tax		(3,369,989)		(586,656)
Income tax expense		—		—
Net loss	$	(3,369,989)	$	(586,656)
Basic and diluted weighted average shares outstanding of Class A common stock subject to possible redemption		10,049,964		9,925,703
Basic and diluted net income per share, Class A common stock subject to possible redemption	$	—	$	—
Basic and diluted weighted average shares outstanding of non-redeemable common stock		4,325,036		4,147,748
Basic and diluted net loss per share, non-redeemable common stock	$	(0.78)	$	(0.14)


General and administrative expenses	$	143,888
Franchise tax expense		48,817
Loss from operations		(192,705)
Other income (expense)
Change in fair value of derivative warrant liabilities		3,327,000
Financing costs - derivative warrant liabilities		(360,610)
Income from investments held in Trust Account		9,648
Net income	$	2,783,333
Basic and diluted weighted average shares outstanding of Class A common stock subject to possible redemption		9,743,321
Basic and diluted net income per share, Class A common stock subject to possible redemption	$	—
Basic and diluted weighted average shares outstanding of Non-redeemable common stock		3,968,490
Basic and diluted net income per share, Non-redeemable common stock	$	0.70

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~The accompanying notes are an integral part of these unaudited condensed financial statements.~~

2Table of Contents

~~Table~~CA ofHEALTHCARE ~~Contents~~ACQUISITION CORP.

CAUNAUDITED ~~HEALTHCARE~~CONDENSED ~~ACQUISITION~~STATEMENTS ~~CORP.~~OF CHANGES IN STOCKHOLDERS’ EQUITY

~~UNAUDITED CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY~~

FOR THE THREE MONTHS ENDED MARCH 31, 2021


	For the three and six months ended June 30, 2021
	Common Stock						Additional		Retained Earnings		Total
	Class A			Class B			Paid-In		(Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit)		Equity
Balance — December 31, 2020	—	$	—	2,875,000	$	288	$	24,712	$	(2,263)	$	22,737
Sale of units in initial public offering, less fair value of public warrants	11,500,000		1,150	—		—		109,191,350		—		109,192,500
Offering costs	—		—	—		—		(6,461,892)		—		(6,461,892)
Class A common stock subject to possible redemption	(10,053,667)		(1,005)	—		—		(100,535,665)		—		(100,536,670)
Net income	—		—	—		—		—		2,783,333		2,783,333
Balance - March 31, 2021 (Unaudited)	1,446,333		145	2,875,000		288		2,218,505		2,781,070		5,000,008
Class A common stock subject to possible redemption	336,999		33	—		—		3,369,957		—		3,369,990
Net loss	—		—	—		—		—		(3,369,989)		(3,369,989)
Balance - June 30, 2021 (Unaudited)	1,783,332	$	178	2,875,000	$	288	$	5,588,462	$	(588,919)	$	5,000,009


	Common Stock						Additional		Retained Earnings		Total
	Class A			Class B			Paid-In		(Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit)		Equity
Balance — December 31, 2020	—	$	—	2,875,000	$	288	$	24,712	$	(2,263)	$	22,737
Sale of units in initial public offering, less fair value of public warrants	11,500,000		1,150	—		—		109,191,350		—		109,192,500
Offering costs	—		—	—		—		(6,461,892)		—		(6,461,892)
Class A common stock subject to possible redemption	(10,053,667)		(1,005)	—		—		(100,535,665)		—		(100,536,670)
Net income	—		—	—		—		—		2,783,333		2,783,333
Balance — March 31, 2021	1,446,333	$	145	2,875,000	$	288	$	2,218,505	$	2,781,070	$	5,000,008

The accompanying notes are an integral part of these unaudited condensed financial statements.

~~The accompanying notes are an integral part of these unaudited condensed financial statements.~~

Table of Contents

3CA HEALTHCARE ACQUISITION CORP.

~~Table~~UNAUDITED ofCONDENSED ~~Contents~~STATEMENT OF CASH FLOWS

CAFOR ~~HEALTHCARE~~THE ~~ACQUISITION~~SIX ~~CORP.~~MONTHS ENDED JUNE 30, 2021

~~UNAUDITED CONDENSED STATEMENT OF CASH FLOWS~~

FOR THE THREE MONTHS ENDED MARCH 31, 2021


Cash Flows from Operating Activities:
Net loss	$	(586,656)
Adjustments to reconcile net loss to net cash used in operating activities:
General and administrative expenses paid through note payable to Sponsor		1,871
Change in fair value of derivative warrant liabilities		(270,500)
Offering costs - derivative warrant liabilities		360,610
Income from investments held in Trust Account		(12,434)
Changes in operating assets and liabilities:
Prepaid expenses		(328,863)
Accounts payable		15,750
Accrued expenses		15,288
Franchise tax payable		49,362
Due to related party		2,275
Net cash used in operating activities		(753,297)

Cash Flows from Investing Activities
Cash deposited in Trust Account		(115,000,000)
Net cash used in investing activities		(115,000,000)

Cash Flows from Financing Activities:
Repayment of note payable to related party		(133,770)
Proceeds received from initial public offering, gross		115,000,000
Proceeds received from private placement warrant		4,050,000
Offering costs paid		(2,548,755)
Net cash provided by financing activities		116,367,475

Net increase in cash		614,178

Cash — beginning of the period		9,498
Cash — end of the period	$	623,676

Supplemental disclosure of noncash activities:
Offering costs paid through note payable to Sponsor	$	12,547
Offering costs included in accrued expenses	$	95,000
Deferred underwriting commissions in connection with the initial public offering	$	4,025,000
Initial value of Class A common stock subject to possible redemption	$	97,382,330
Change in value of Class A common stock subject to possible redemption	$	(215,650)


Cash Flows from Operating Activities:
Net income	$	2,783,333
Adjustments to reconcile net income to net cash used in operating activities:
General and administrative expenses paid through note payable to Sponsor		1,871
Change in fair value of derivative warrant liabilities		(3,327,000)
Financing costs - derivative warrant liabilities		360,610
Income from investments held in Trust Account		(9,648)
Changes in operating assets and liabilities:
Prepaid expenses		(394,984)
Accounts payable		(8,000)
Franchise tax payable		48,817
Due to related party		2,275
Net cash used in operating activities		(542,726)

Cash Flows from Investing Activities
Cash deposited in Trust Account		(115,000,000)
Net cash used in investing activities		(115,000,000)

Cash Flows from Financing Activities:
Repayment of note payable to related party		(133,770)
Proceeds received from initial public offering, gross		115,000,000
Proceeds received from private placement warrant		4,050,000
Offering costs paid		(2,535,880)
Net cash provided by financing activities		116,380,350

Net increase in cash		837,624

Cash — beginning of the period		9,498
Cash — end of the period	$	847,122

Supplemental disclosure of noncash activities:
Initial classification of warrant liability	$	9,857,500
Offering costs paid through note payable to Sponsor	$	12,547
Offering costs included in accounts payable	$	12,875
Offering costs included in accrued expenses	$	95,000
Deferred underwriting commissions in connection with the initial public offering	$	4,025,000
Initial value of Class A common stock subject to possible redemption	$	97,382,330
Change in value of Class A common stock subject to possible redemption	$	3,154,340

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

4CA HEALTHCARE ACQUISITION CORP.

~~Table~~NOTES ofTO ~~Contents~~UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 1—Description of Organization and Business Operations

CA Healthcare Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on October 7, 2020 (inception). The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of ~~March 31~~June 30, 2021, the Company had not yet commenced ~~any~~ operations. All activity ~~for~~since ~~the~~inception ~~period~~through ~~from~~June ~~January 1~~30, 2021 ~~through~~related ~~March 31, 2021 relates~~ to the Company’s formation and the Initial Public Offering (as defined below), and, subsequent to the Initial Public Offering, the search for a target for its initial Business Combination.

The Company’s sponsor is CA Healthcare Sponsor LLC, a Delaware limited liability company controlled by certain of the Company’s officers, directors and advisors (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective by the Securities and Exchange Commission on January 26, 2021. On January 29, 2021, the Company consummated its Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), including 1,500,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $115.0 million, and incurring offering costs of approximately $6.5 million, of which approximately $4.0 million was for deferred underwriting commissions (Note 6).

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) to the Sponsor of 4,050,000 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $4.1 million (Note 5).

Upon the closing of the Initial Public Offering and the Private Placement, $115.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”) in the United States , with Continental Stock Transfer & Trust Company acting as trustee, and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any money market funds meeting certain conditions of Rule 2a-7 of the Investment Company Act, which invest only in direct U.S, government treasury obligations until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Nasdaq rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholders meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek stockholder approval of a Business Combination at a meeting called for such purpose at which public stockholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination.5

5Table of Contents

~~Table~~CA ofHEALTHCARE ~~Contents~~ACQUISITION CORP.

~~The~~NOTES ~~Company~~TO ~~will~~UNAUDITED ~~proceed~~CONDENSED ~~with~~FINANCIAL a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.STATEMENTS

IfThe ~~the~~ Company ~~seeks~~will ~~stockholder~~provide ~~approval~~its holders of athe ~~Business~~outstanding ~~Combination~~Public ~~and~~Shares it(the ~~does~~“Public ~~not~~Stockholders”) ~~conduct~~with ~~redemptions~~the ~~pursuant~~opportunity to ~~the~~redeem ~~tender~~all ~~offer~~or ~~rules,~~a ~~the~~portion ~~Company’s~~of ~~Amended~~their ~~and~~Public ~~Restated~~Shares ~~Certificate~~upon ofthe ~~Incorporation~~completion ~~provides~~of ~~that,~~ a ~~Public~~Business ~~Stockholder,~~Combination ~~together~~either (i) in connection with ~~any~~a ~~affiliate~~stockholders ofmeeting ~~such~~called ~~stockholder~~to orapprove ~~any~~the ~~other~~Business ~~person~~Combination ~~with~~or ~~whom~~(ii) by ~~such~~means ~~stockholder~~of isa ~~acting~~tender inoffer. ~~concert~~In orconnection aswith a ~~“group”~~proposed ~~(as~~Business ~~defined~~Combination, ~~under~~the ~~Section 13~~Company ofmay ~~the~~seek ~~Securities~~stockholder ~~Exchange~~approval ~~Act~~ of ~~1934,~~a asBusiness ~~amended~~Combination ~~(the~~at ~~“Exchange~~a ~~Act”)),~~meeting ~~will~~called befor ~~restricted~~such ~~from~~purpose ~~seeking~~at ~~redemption~~which ~~rights~~public ~~with~~stockholders ~~respect~~may seek to ~~15%~~redeem ortheir ~~more~~shares, regardless of ~~the~~whether ~~Public~~they ~~Shares~~vote ~~without~~for ~~the~~or ~~Company’s~~against ~~prior~~a ~~written~~Business ~~consent~~Combination.

The ~~Public~~Company ~~Stockholders~~ will beproceed ~~entitled~~with ~~to redeem their shares for~~ a ~~pro~~Business ~~rata~~Combination ~~portion~~only ofif the ~~amount~~Company ~~then~~has innet ~~the~~tangible ~~Trust~~assets ~~Account~~of ~~($10.00~~at ~~per~~least ~~share~~$5,000,001 ~~plus~~either ~~any~~immediately ~~pro~~prior ~~rata interest earned on the funds held in the Trust Account and not previously released~~ to ~~the~~or Company to pay its tax obligations). The per-share amount to be distributed to Public Stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the representative of the underwriters (as discussed in Note 6). There will be no redemption rights upon ~~the~~such ~~completion~~consummation of a Business Combination ~~with~~and, ~~respect~~if to the Company’s ~~warrants.~~seeks ~~These~~stockholder ~~shares~~approval, ~~of Class A common stock were recorded at~~ a ~~redemption~~majority ~~value~~of ~~and~~the ~~classified~~outstanding asshares ~~temporary~~voted ~~equity~~are ~~upon~~voted ~~the~~in ~~completion~~favor of the ~~Initial~~Business ~~Public Offering, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity~~Combination.”

If athe Company seeks stockholder ~~vote~~approval isof ~~not~~a ~~required~~Business Combination and ~~the~~it ~~Company~~ does not ~~decide~~conduct redemptions pursuant to ~~hold~~the atender ~~stockholder~~offer ~~vote~~rules, ~~for~~the ~~business~~Company’s orAmended ~~other~~and ~~legal~~Restated ~~reasons,~~Certificate ~~the~~of ~~Company~~Incorporation ~~will~~provides that, ~~pursuant~~a toPublic ~~its~~Stockholder, ~~Amended~~together ~~and~~with ~~Restated~~any ~~Certificate~~affiliate of ~~Incorporation,~~such ~~offer~~stockholder or any other person with whom such ~~redemption~~stockholder ~~pursuant~~is toacting ~~the~~in ~~tender~~concert ~~offer~~or ~~rules~~as a “group” (as defined under Section 13 of the Securities ~~and~~ Exchange ~~Commission~~Act of 1934, as amended (the “~~SEC~~Exchange Act”)), ~~and~~will ~~file~~be ~~tender~~restricted ~~offer~~from ~~documents~~seeking ~~containing~~redemption ~~substantially~~rights ~~the~~with ~~same~~respect ~~information~~to as15% ~~would~~or bemore ~~included~~of inthe aPublic ~~proxy~~Shares ~~statement~~without ~~with~~ the ~~SEC~~Company’s prior towritten ~~completing a Business Combination~~consent.

The ~~Company’s~~Public ~~Sponsor~~Stockholders ~~agreed~~will ~~(a)~~be entitled to ~~vote~~redeem ~~its~~their ~~Founder~~shares ~~Shares~~for ~~(as~~a ~~defined~~pro inrata ~~Note~~portion 5)of ~~and~~the ~~any~~amount ~~Public~~then ~~Shares~~in ~~purchased during or after~~ the ~~Initial~~Trust ~~Public~~Account ~~Offering~~($10.00 inper ~~favor~~share, ofplus aany ~~Business~~pro ~~Combination,~~rata ~~(b) not~~interest toearned ~~propose~~on anthe ~~amendment~~funds toheld in the ~~Company’s~~Trust ~~Amended~~Account and ~~Restated~~not ~~Certificate~~previously ofreleased ~~Incorporation with respect~~ to the Company’s ~~pre-Business Combination activities prior~~ to ~~the~~pay ~~consummation~~its oftax aobligations). ~~Business~~The ~~Combination~~per-share ~~unless~~amount ~~the~~to ~~Company~~be ~~provides~~distributed ~~dissenting~~to Public Stockholders ~~with~~who ~~the opportunity to~~ redeem their ~~Public~~shares ~~Shares~~will innot ~~conjunction~~be ~~with~~reduced ~~any~~by ~~such~~the ~~amendment~~deferred ;underwriting ~~(c)~~commissions ~~not~~the toCompany ~~redeem~~will ~~any~~pay ~~shares~~to ~~(including~~ the ~~Founder~~representative ~~Shares)~~of ~~and~~the ~~Private~~underwriters ~~Placement~~(as ~~Warrants~~discussed ~~(including~~in ~~underlying~~Note ~~securities~~6). ~~into~~There ~~the~~will ~~right~~be tono ~~receive~~redemption ~~cash~~rights ~~from~~upon the ~~Trust~~completion ~~Account~~of ~~in connection with~~ a ~~stockholder vote to approve a~~ Business Combination ~~(or~~with respect to ~~sell~~the ~~any~~Company’s ~~shares~~warrants. inThese ashares ~~tender~~of ~~offer~~Class inA ~~connection~~common ~~with~~stock awere ~~Business~~recorded ~~Combination~~at ifa ~~the~~redemption ~~Company~~value ~~does~~and ~~not~~classified ~~seek~~as ~~stockholder~~temporary ~~approval~~equity inupon ~~connection therewith) or a vote to amend~~ the ~~provisions~~completion of the ~~Amended~~Initial ~~and~~Public ~~Restated~~Offering, ~~Certificate~~in ofaccordance ~~Incorporation~~with ~~relating~~Financial toAccounting ~~stockholders’~~Standards ~~rights~~Board ~~of pre-Business Combination activity and~~ (d“FASB”) ~~that~~Accounting ~~the~~Standards ~~Founder~~Codification ~~Shares and Private Placement Warrants~~ (~~including underlying securities~~“ASC”) ~~shall~~Topic ~~not~~480 ~~participate~~“Distinguishing inLiabilities ~~any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions~~ from ~~the~~Equity" ~~Trust~~("ASC ~~Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination~~480").

6If a stockholder vote is not required and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.

~~Table~~The Company’s Sponsor agreed (a) to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of ~~Contents~~a Business Combination, (b) not to propose an amendment to the Company’s Amended and Restated Certificate of Incorporation with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment ; (c) not to redeem any shares (including the Founder Shares) and Private Placement Warrants (including underlying securities) into the right to receive cash from the Trust Account in connection with a stockholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek stockholder approval in connection therewith) or a vote to amend the provisions of the Amended and Restated Certificate of Incorporation relating to stockholders’ rights of pre-Business Combination activity and (d) that the Founder Shares and Private Placement Warrants (including underlying securities) shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.

If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or January 29, 2023 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirement of applicable law. The representative of the underwriters agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).6

~~The~~Table Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the day of liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.Contents

~~Liquidity~~CA ~~and~~HEALTHCARE ~~Capital~~ACQUISITION ~~Resources~~CORP.

AsNOTES ofTO ~~March~~UNAUDITED ~~31,~~CONDENSED ~~2021,~~FINANCIAL ~~the Company had approximately $847,000 in cash and working capital of approximately $1.1 million.~~STATEMENTS

~~The~~If the Company’s ~~liquidity~~is ~~needs~~unable to ~~date~~complete ~~have~~a ~~been~~Business ~~satisfied~~Combination ~~through~~within a24 ~~cash~~months ~~payment~~from ofthe ~~$25,000~~closing ~~from~~of the ~~Sponsor~~Initial toPublic ~~purchase~~Offering, ~~the~~or ~~Founder~~January ~~Shares~~29, 2023 (asthe ~~defined~~“Combination ~~in Note 5~~Period”), the ~~loan~~Company ~~under~~will (i) cease all operations except for the ~~Note~~purpose of ~~approximately~~winding ~~$134~~up,~~000~~ (ii) as ~~defined~~promptly inas ~~Note~~reasonably 5)possible but no more than ten business days thereafter, ~~and~~redeem the ~~net~~Public ~~proceeds~~Shares, ~~from~~at a per-share price, payable in cash, equal to the ~~consummation~~aggregate ofamount then on deposit in the ~~Private~~Trust ~~Placement~~Account, ~~not~~including interest earned on the funds held in the Trust Account. ~~The~~and not previously released to the Company ~~fully~~to ~~repaid~~pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the ~~Note~~number onof ~~January~~then 29outstanding Public Shares, ~~2021.~~which Inredemption ~~addition~~will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, inif ~~order~~any), subject to ~~finance~~applicable ~~transaction~~law, ~~costs~~and in(iii) as ~~connection~~promptly ~~with~~as anreasonably ~~Initial~~possible ~~Business~~following ~~Combination~~such redemption, subject to the approval of the remaining stockholders and the Company’s ~~officers,~~board of directors, proceed to commence a voluntary liquidation and ~~initial~~thereby ~~stockholders~~a ~~may~~formal dissolution of the Company, ~~but~~subject ~~are~~in ~~not~~each ~~obligated~~case to, its obligations to provide for claims of creditors and the requirement of applicable law. The representative of the underwriters agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company ~~Working~~does ~~Capital~~not ~~Loans~~complete ~~(see~~a ~~Note~~Business 5)Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. AsIn the event of ~~March~~such 31distribution, ~~2021,~~it ~~there~~is ~~were~~possible nothat ~~amounts~~the ~~outstanding~~per ~~under~~share ~~any~~value ~~Working~~of ~~Capital~~the ~~Loans~~assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

AsThe ofSponsor ~~March~~agreed 31that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, ~~2021~~or a prospective target business with which the Company has entered into a written letter of intent, ~~there~~confidentiality isor ansimilar ~~outstanding~~agreement ~~balance~~or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $210.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the day of liquidation of the Trust Account,~~275~~ if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for ~~certain~~such ~~reimbursable~~indemnification ~~expenses~~obligations, ~~and~~nor ~~other~~has ~~expenses~~the ~~paid~~Company onindependently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations. None of the Company’s ~~behalf~~officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

~~Based~~Liquidity ~~on the foregoing, management believes that the Company will have sufficient working capital~~ and ~~borrowing~~Capital capacity to meet its needs through the earlier of the consummation of an Initial Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective Initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Initial Business Combination.Resources

7As of June 30, 2021, the Company had approximately $624,000 in cash and working capital of approximately $816,000.

~~Table~~The Company’s liquidity needs through June 30, 2021 and prior were satisfied through a cash payment of ~~Contents~~$25,000 from the Sponsor to purchase the Founder Shares (as defined in Note 5), the loan under the Note of approximately $134,000 (as defined in Note 5), and the net proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the Note on January 29, 2021. In addition, in order to finance transaction costs in connection with an Initial Business Combination, the Company’s officers, directors and initial stockholders may, but are not obligated to, provide the Company Working Capital Loans (see Note 5). As of June 30, 2021 and December 31, 2020, there were no amounts outstanding under any Working Capital Loans.

~~Risks~~As of June 30, 2021, there is an outstanding balance of $2,275 due to the Sponsor for certain reimbursable expenses and ~~Uncertainties~~other expenses paid on the Company’s behalf.

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.7

Table of Contents

CA HEALTHCARE ACQUISITION CORP.

~~Note~~NOTES ~~2—Revision~~TO toUNAUDITED ~~Prior~~CONDENSED ~~Period~~FINANCIAL ~~Financial Statements~~STATEMENTS

Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of an Initial Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective Initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Initial Business Combination.

~~During~~Risks ~~the~~and course of preparing the quarterly report on Form 10-Q for the three-month period ended March 31, 2021, the Company identified a misstatement in its misapplication of accounting guidance related to the Company’s Warrants in the Company’s previously issued audited balance sheet dated January 29, 2021, filed on Form 8-K on February 4, 2021 (the “Post-IPO Balance Sheet”).Uncertainties

On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since their issuance on January 29, 2021, the Company’s warrants have been accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, including with the Company’s independent registered public accounting firm and the Company’s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement.

Potential Business Combination

The Warrants were reflected as a component of equity in the Post-IPO Balance Sheet as opposed to liabilities on the balance sheet, based on the Company’s application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for Warrants issued on January 29, 2021, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company’s statement of operations each reporting period.

On April 6, 2021, the Company, LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("LumiraDx") and LumiraDx Merger Sub, Inc., a newly formed Delaware corporation and wholly owned subsidiary of LumiraDx ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement") that, among other things, provides for Merger Sub to be merged with and into the Company with the Company being the surviving corporation in the merger (the "Merger"). As a result of and upon consummation of the Merger, the Company will become a wholly owned subsidiary of LumiraDx, with security holders of the Company becoming security holders of LumiraDx. The Merger Agreement contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Merger and the other transactions contemplated thereby. The consummation of the transactions contemplated by the Merger Agreement is subject to the satisfaction (or waiver) of the conditions set forth therein.

~~Table of Contents~~

~~The~~Note ~~Company~~2—Revision ~~concluded that the misstatement was not material~~ to ~~the~~Prior ~~Post-IPO~~Period ~~Balance~~Financial ~~Sheet and the misstatement had no material impact to any prior interim period. The effect of the revisions to the Post-IPO Balance Sheet is as follows:~~Statements


	As of January 29, 2021
	As Previously		Restatement
	Reported		Adjustment		As Restated
Balance Sheet
Total assets	$	116,643,903	$	—	$	116,643,903
Liabilities and stockholders’ equity
Total current liabilities	$	379,064	$	—	$	379,064
Deferred underwriting commissions		4,025,000		—		4,025,000
Derivative warrant liabilities		—		9,857,500		9,857,500
Total liabilities		4,404,064		9,857,500		14,261,564
Class A common stock, $0.0001 par value; shares subject to possible redemption		107,239,830		(9,857,500)		97,382,330
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		78		98		176
Class B common stock - $0.0001 par value		288		—		288
Additional paid-in-capital		5,020,028		360,512		5,380,540
Accumulated deficit		(20,385)		(360,610)		(380,995)
Total stockholders’ equity		5,000,009		—		5,000,009
Total liabilities and stockholders’ equity	$	116,643,903	$	—	$	116,643,903

During the course of preparing the quarterly report on Form 10-Q for the three-month period ended March 31, 2021, the Company identified a misstatement in its misapplication of accounting guidance related to the Company’s Warrants in the Company’s previously issued audited balance sheet dated January 29, 2021, filed on Form 8-K on February 4, 2021 (the “Post-IPO Balance Sheet”).

On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since their issuance on January 29, 2021, the Company’s warrants have been accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation with the Company’s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement.

~~Note 3—Basis of Presentation and Summary of Significant Accounting Policies~~8

~~Basis~~Table of ~~Presentation~~Contents

~~The~~CA ~~accompanying~~HEALTHCARE ~~unaudited~~ACQUISITION condensed financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and Article 8 of Regulation S-XCORP. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or any future period.

~~The~~NOTES ~~accompanying~~TO ~~unaudited~~UNAUDITED ~~condensed~~CONDENSED ~~financial~~FINANCIAL statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 8-K and the final prospectus filed by the Company with the SEC on February 4, 2021 and January 27, 2021, respectively.STATEMENTS

InThe ~~April~~Warrants ~~2021,~~were ~~the~~reflected ~~Company identified an error in its accounting treatment for both its public and private warrants (Warrants)~~ as ~~presented~~a incomponent ~~its audited balance sheet as~~ of ~~January~~equity ~~29, 2021 included~~ in ~~its~~the ~~Current Report on Form 8~~Post-K.IPO ~~The~~Balance ~~Warrants~~Sheet ~~were reflected~~ as ~~a component of equity as~~ opposed to liabilities on the balance sheet., ~~Pursuant~~based toon ~~Accounting~~the ~~Standards~~Company’s ~~Codification~~application (“of FASB ASC”) ~~250~~Topic 815-40, ~~Accounting~~Derivatives ~~Changes~~ and ~~Error~~Hedging, ~~Corrections~~Contracts ~~issued~~in byEntity’s ~~the~~Own ~~Financial~~Equity ~~Accounting Standards Board~~ (“~~FASB”)~~ASC ~~and Staff Accounting Bulletin 99, “Materiality”~~815-40). ~~(“SAB~~The ~~99”)~~views ~~issued~~expressed byin the SEC, ~~the~~Staff ~~Company~~Statement ~~determined~~were ~~the~~not ~~impact~~consistent ofwith the ~~error~~Company’s ~~was~~historical ~~immaterial.~~interpretation ~~The impact~~ of the ~~error~~specific ~~correction~~provisions iswithin ~~reflected~~its inwarrant ~~the~~agreement ~~unaudited~~and ~~condensed~~the ~~financial~~Company’s ~~statements~~application ~~contained~~of ~~herein~~ASC ~~which~~815-40 ~~resulted~~to inthe awarrant ~~$10~~agreement.0 ~~million~~The ~~increase~~Company toreassessed ~~the~~its ~~derivative~~accounting ~~warrant~~for ~~liabilities~~Warrants ~~line~~issued ~~item~~on ~~and~~January ~~offsetting~~29, ~~decrease~~2021, toin ~~the~~light ~~Class~~of Athe ~~common~~SEC ~~stock~~Staff’s ~~subject~~published toviews. ~~possible~~Based ~~redemption~~on ~~mezzanine~~this ~~equity~~reassessment, ~~line~~management ~~item~~determined ~~recorded~~that ~~as part of~~ the ~~activity~~Warrants inshould ~~the~~be ~~period~~classified ~~from~~as ~~October~~liabilities 7,measured ~~2020~~at ~~(inception)~~fair ~~through~~value ~~March~~upon 31issuance, ~~2021~~with assubsequent ~~reported~~changes ~~herein. There~~in ~~would~~fair ~~have~~value ~~been~~reported noin ~~change~~the toCompany’s ~~total~~statement ~~stockholders’~~of ~~equity~~operations aseach ~~reported~~reporting period.

~~Table~~The Company concluded that the misstatement was not material to the Post-IPO Balance Sheet and the misstatement had no material impact to any prior interim period. The effect of ~~Contents~~the revisions to the Post-IPO Balance Sheet is as follows:

~~Emerging Growth Company~~

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.


	As of January 29, 2021
	As Previously		Restatement
	Reported		Adjustment		As Restated
Balance Sheet
Total assets	$	116,643,903	$	—	$	116,643,903
Liabilities and stockholders’ equity
Total current liabilities	$	379,064	$	—	$	379,064
Deferred underwriting commissions		4,025,000		—		4,025,000
Derivative warrant liabilities		—		9,857,500		9,857,500
Total liabilities		4,404,064		9,857,500		14,261,564
Class A common stock, $0.0001 par value; shares subject to possible redemption		107,239,830		(9,857,500)		97,382,330
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		78		98		176
Class B common stock - $0.0001 par value		288		—		288
Additional paid-in-capital		5,020,028		360,512		5,380,540
Accumulated deficit		(20,385)		(360,610)		(380,995)
Total stockholders’ equity		5,000,009		—		5,000,009
Total liabilities and stockholders’ equity	$	116,643,903	$	—	$	116,643,903

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

~~Use of Estimates~~

~~The~~Note ~~preparation~~3—Basis of ~~financial~~Presentation ~~statements in conformity with GAAP requires the Company’s management to make estimates~~ and ~~assumptions~~Summary ~~that affect the reported amounts~~ of ~~assets~~Significant ~~and~~Accounting liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.Policies

~~Cash~~Basis ~~and~~of ~~Cash Equivalents~~Presentation

The accompanying unaudited condensed financial statements of the Company ~~considers~~have ~~all~~been ~~short-term~~prepared ~~investments~~in accordance with anUnited ~~original~~States ~~maturity~~generally accepted accounting principles (“GAAP”) for interim financial information and Article 8 of ~~three~~Regulation ~~months~~S-X. orAccordingly, ~~less~~they ~~when~~do ~~purchased~~not toinclude beall ~~cash~~of ~~equivalents~~the information and footnotes required by GAAP. AsIn the opinion of ~~March~~management, 31all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Operating results for the three and six months ended June 30, 2021, ~~there~~are ~~were~~not nonecessarily ~~cash~~indicative ~~equivalents~~of the results that may be expected for the year ending December 31, 2021.

~~Investments Held in Trust Account~~9

~~The~~Table ~~Company’s portfolio~~ of investments is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income from investments held in Trust Account in the accompanying unaudited condensed statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.Contents

10CA HEALTHCARE ACQUISITION CORP.

~~Table~~NOTES ofTO ~~Contents~~UNAUDITED CONDENSED FINANCIAL STATEMENTS

~~Concentration~~In April 2021, the Company identified an error in its accounting treatment for both its public and private warrants (Warrants) as presented in its audited balance sheet as of ~~Credit~~January ~~Risk~~29, 2021 included in its Current Report on Form 8-K. The Warrants were reflected as a component of equity as opposed to liabilities on the balance sheet. Pursuant to FASB ASC Topic 250, “Accounting Changes and Error Corrections issued by the FASB and Staff Accounting Bulletin 99,” (“Materiality”) (“SAB 99”) issued by the SEC, the Company determined the impact of the error was immaterial. The impact of the error correction was reflected in the unaudited condensed financial statements as of and for the three months ended March 31, 2021 which resulted in a $10.0 million increase to the derivative warrant liabilities line item and offsetting decrease to the Class A common stock subject to possible redemption mezzanine equity line item recorded as part of the activity in the period from October 7, 2020 (inception) through March 31, 2021. There was no change to total stockholders’ equity as reported.

~~Financial~~Emerging ~~instruments~~Growth ~~that potentially subject the~~ Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000 and investments held in Trust Account. As of March 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

~~Fair~~The ~~Value~~Company is an “emerging growth company,” as defined in Section 2(a) of ~~Financial~~the ~~Instruments~~Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

~~Fair~~Further, ~~value~~Section is102(b)(1) ~~defined~~of as the ~~price~~JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that ~~would~~is, bethose ~~received~~that ~~for~~have ~~sale~~not ofhad ana ~~asset~~Securities Act registration statement declared effective or ~~paid~~do ~~for~~not ~~transfer~~have a class of asecurities ~~liability,~~registered inunder anthe ~~orderly~~Exchange ~~transaction~~Act) ~~between~~are ~~market~~required ~~participants~~to atcomply with the ~~measurement~~new ~~date.~~or Urevised financial accounting standards.S. ~~GAAP~~The ~~establishes~~JOBS aAct ~~three~~provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-~~tier~~emerging ~~fair~~growth ~~value~~companies ~~hierarchy~~but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which ~~prioritizes~~means that when a standard is issued or revised and it has different application dates for public or private companies, the ~~inputs~~Company, ~~used~~as inan ~~measuring~~emerging ~~fair~~growth ~~value~~company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

~~The~~This ~~hierarchy~~may ~~gives~~make comparison of the ~~highest~~Company’s ~~priority~~unaudited tocondensed ~~unadjusted~~financial ~~quoted~~statements ~~prices~~with inanother ~~active~~public ~~markets~~company ~~for~~that ~~identical~~is ~~assets~~neither oran ~~liabilities~~emerging ~~(Level~~growth 1company ~~measurements)~~nor ~~and~~an emerging growth company that has opted out of using the ~~lowest~~extended ~~priority~~transition toperiod ~~unobservable~~difficult ~~inputs~~or ~~(Level~~impossible 3because ~~measurements).~~of ~~These~~the ~~tiers~~potential ~~include:~~differences in accounting standards used.

●Use ~~Level~~of ~~1, defined as observable inputs such as quoted prices for identical instruments in active markets;~~Estimates

●The ~~Level~~preparation 2,of ~~defined~~financial asstatements ~~inputs~~in ~~other~~conformity ~~than~~with ~~quoted~~GAAP ~~prices~~requires inthe ~~active~~Company’s ~~markets~~management to make estimates and assumptions that ~~are~~affect ~~either~~the ~~directly~~reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or ~~indirectly~~set ~~observable~~of ~~such~~circumstances asthat ~~quoted~~existed ~~prices~~at ~~for~~the ~~similar~~date ~~instruments~~of the unaudited condensed financial statements, which management considered in ~~active~~formulating ~~markets~~its orestimate, ~~quoted~~could ~~prices~~change ~~for~~in ~~identical~~the near term due to one or ~~similar~~more ~~instruments~~future inconfirming ~~markets~~events. ~~that~~Accordingly, ~~are~~the ~~not~~actual ~~active;~~results ~~and~~could differ significantly from those estimates.

●Cash ~~Level~~and 3,Cash defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.Equivalents

InThe ~~some~~Company ~~circumstances,~~considers ~~the~~all ~~inputs~~short-term ~~used~~investments towith ~~measure~~an ~~fair~~original ~~value~~maturity ~~might~~of bethree ~~categorized~~months ~~within~~or ~~different~~less ~~levels~~when ofpurchased ~~the~~to ~~fair~~be ~~value~~cash ~~hierarchy~~equivalents. InAs ~~those~~of ~~instances~~June 30, ~~the~~2021 ~~fair~~and ~~value~~December ~~measurement~~31, is2020, ~~categorized~~there inwere ~~its~~no ~~entirety~~cash ~~in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement~~equivalents.

As of March 31, 2021, the carrying values of cash, prepaid expenses, accounts payable, accrued expenses, franchise tax payable, and due to related party approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in money market funds that invest in U.S. government securities, or a combination thereof. The fair value for trading securities is determined using quoted market prices in active markets.10

~~Derivative~~Table ~~warrant~~of ~~liabilities~~Contents

~~The~~CA ~~Company~~HEALTHCARE ~~does~~ACQUISITION ~~not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks~~CORP. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

~~The~~NOTES ~~5,750,000~~TO ~~issued~~UNAUDITED inCONDENSED ~~connection~~FINANCIAL with the Initial Public Offering (the “Public Warrants”) and the 4,050,000 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations.STATEMENTS

11Investments Held in Trust Account

~~Table~~The Company’s portfolio of ~~Contents~~investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income from investments held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

~~The~~Concentration ~~fair value~~ of ~~warrants~~Credit issued in connection with the Initial Public Offering were initially measured at fair value using a Monte Carlo simulation model. The fair value of the warrants issued in the Private Placement were estimated using Black-Scholes.Risk

~~Offering~~Financial ~~Costs~~instruments ~~Associated~~that ~~with~~potentially subject the ~~Initial~~Company ~~Public~~to ~~Offering~~concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000 and investments held in Trust Account. As of June 30, 2021 and December 31, 2020, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

~~Offering~~Fair ~~costs~~Value ~~consisted~~ of ~~legal,~~Financial accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A common stock were charged to stockholders’ equity upon the completion of the Initial Public Offering. Of the total offering costs of the Initial Public Offering, approximately $0.3 million is included in financing cost - derivative warrant liabilities in the unaudited condensed statement of operations and $6.5 million is included in stockholders’ equity.Instruments

~~Class~~Fair Avalue ~~common~~is ~~stock~~defined ~~subject~~as tothe ~~possible~~price ~~redemption~~that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

The ~~Company~~hierarchy ~~accounts~~gives ~~for~~the ~~its~~highest ~~Class~~priority ~~A common stock subject~~ to ~~possible~~unadjusted ~~redemption~~quoted inprices ~~accordance with the guidance~~ in ~~ASC~~active ~~Topic~~markets ~~480~~for ~~“Distinguishing~~identical ~~Liabilities~~assets ~~from~~or ~~Equity.”~~liabilities ~~Class A common stock subject to mandatory redemption~~ (ifLevel ~~any~~1 measurements) ~~is classified as liability instruments~~ and ~~are measured at fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within~~ the ~~control~~lowest ofpriority ~~the holder or subject~~ to ~~redemption~~unobservable ~~upon~~inputs ~~the~~(Level ~~occurrence~~3 ~~of uncertain events not solely within the Company’s control~~measurements) ~~are classified as temporary equity~~. AtThese ~~all~~tiers ~~other~~consist ~~times, Class A common stock is classified as stockholders’ equity. The Company’s Class A common stock feature certain redemption rights that are considered to be outside~~ of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at March 31, 2021, 10,053,667 shares of Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets.:

~~Income~~● ~~Taxes~~Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

~~The~~● ~~Company~~Level ~~follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740~~2, ~~“Income~~defined ~~Taxes”~~as ~~(“ASC~~inputs ~~740”).~~other ~~Deferred~~than ~~tax~~quoted ~~assets~~prices ~~and~~in ~~liabilities~~active ~~are~~markets ~~recognized~~that for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are ~~measured~~either ~~using~~directly ~~enacted~~or ~~tax~~indirectly ~~rates~~observable ~~expected~~such toas ~~apply~~quoted toprices ~~taxable~~for ~~income~~similar ininstruments ~~the years~~ in ~~which~~active ~~those~~markets ~~temporary~~or ~~differences~~quoted ~~are~~prices ~~expected~~for toidentical ~~be recovered~~ or ~~settled.~~similar ~~The~~instruments ~~effect on deferred tax assets and liabilities of a change~~ in ~~tax~~markets ~~rates is recognized in income in the period~~ that ~~included the enactment date. Valuation allowances~~ are ~~established,~~not ~~when~~active; necessary, to reduce deferred tax assets to the amount expected to be realized. As of March 31, 2021, the Company had deferred tax assets of approximately $38,000 with a full valuation allowance against them.and

~~FASB~~● ~~ASC~~Level ~~Topic~~3, ~~740~~defined ~~prescribes~~as aunobservable ~~recognition~~inputs ~~threshold~~in ~~and~~which alittle ~~measurement attribute for the financial statement recognition and measurement of tax positions taken~~ or ~~expected~~no tomarket bedata ~~taken in a tax return. For those benefits to be recognized~~exists, atherefore ~~tax~~requiring ~~position~~an ~~must~~entity ~~be more likely than not~~ to bedevelop ~~sustained~~its ~~upon~~own ~~examination by taxing authorities. There were no unrecognized tax benefits as of March 31~~assumptions, ~~2021.~~such ~~The Company recognizes accrued interest and penalties related to unrecognized tax benefits~~ as ~~income~~valuations ~~tax~~derived ~~expense.~~from ~~The~~valuation ~~Company’s~~techniques ~~currently taxable income primarily consists of interest and dividends earned and unrealized gains on investments held~~ in ~~the~~which ~~Trust~~one ~~Account.~~or ~~The~~more ~~Company’s~~significant ~~general~~inputs ~~and~~or ~~administrative~~significant ~~costs~~value ~~are~~drivers ~~generally considered start-up costs and~~ are ~~not currently deductible~~unobservable.

NoIn ~~amounts~~some ~~were~~circumstances, ~~accrued~~the ~~for~~inputs ~~the~~used ~~payment~~to ofmeasure ~~interest~~fair ~~and~~value ~~penalties~~might asbe ofcategorized ~~March~~within ~~31,~~different ~~2021.~~levels ~~The~~of ~~Company~~the isfair ~~currently~~value ~~not~~hierarchy. ~~aware~~In ofthose ~~any~~instances, ~~issues~~the ~~under~~fair ~~review~~value ~~that~~measurement ~~could~~is ~~result~~categorized in ~~significant~~its ~~payments,~~entirety ~~accruals~~in orthe ~~material~~fair ~~deviation~~value ~~from~~hierarchy ~~its~~based ~~position.~~on ~~The~~the ~~Company~~lowest islevel ~~subject~~input tothat ~~income~~is ~~tax~~significant ~~examinations~~to bythe ~~major~~fair ~~taxing~~value ~~authorities since inception~~measurement.

12As of June 30, 2021, the carrying values of cash, prepaid expenses, accounts payable, accrued expenses, franchise tax payable, and due to related party approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in money market funds that invest in U.S. government securities, or a combination thereof. The fair value for trading securities is determined using quoted market prices in active markets.

~~Table of Contents~~11

~~Net~~Table ~~Income (Loss) Per Share~~ of ~~Common Share~~Contents

~~Net~~CA ~~income~~HEALTHCARE ~~(loss)~~ACQUISITION ~~per common share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period~~CORP. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 9,800,000 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

~~The~~NOTES ~~Company’s~~TO ~~unaudited~~UNAUDITED ~~condensed~~CONDENSED ~~statement~~FINANCIAL of operations includes a presentation of income (loss) per common share for common shares subject to possible redemption in a manner similar to the two-class method of income (loss) per common share. Net income (loss) per common share, basic and diluted, for Class A common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on investments held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of common stock subject to possible redemption outstanding since original issuance.STATEMENTS

~~Net~~Derivative ~~income~~warrant (loss) per share, basic and diluted, for non-redeemable common stock is calculated by dividing the net income (loss), adjusted for income or loss on investments held in the Trust Account attributable to common stock subject to possible redemption, by the weighted average number of non-redeemable common stock outstanding for the period.liabilities

~~Non-redeemable~~The ~~common~~Company ~~stock~~does ~~includes~~not ~~Founder~~use ~~Shares~~derivative ~~and~~instruments ~~non-redeemable~~to ~~shares~~hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of ~~Class~~its Afinancial ~~common~~instruments, including issued stock aspurchase ~~these~~warrants, ~~shares~~to dodetermine ~~not~~if ~~have~~such ~~any~~instruments ~~redemption~~are derivatives or contain features. ~~Non~~that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-~~redeemable~~15. ~~common~~The ~~stock~~classification ~~participates~~of inderivative ~~the~~instruments, ~~income~~including orwhether ~~loss~~such oninstruments ~~investments~~should ~~held~~be inrecorded ~~the~~as ~~Trust~~liabilities ~~Account~~or ~~based~~as onequity, ~~non~~is re-~~redeemable~~assessed ~~shares’~~at ~~proportionate~~the ~~interest~~end of each reporting period.

The ~~following~~5,750,000 ~~table~~issued ~~reflects~~in connection with the ~~calculation~~Initial ofPublic ~~basic~~Offering (the “Public Warrants”) and ~~diluted~~the ~~net~~4,050,000 ~~income~~Private ~~(loss)~~Placement ~~per~~Warrants ~~common~~are ~~share:~~recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s condensed statements of operations.

The fair value of Public Warrants were initially measured at fair value using a Monte Carlo simulation model. The fair value of the warrants issued in the Private Placement were estimated using Black-Scholes. The fair value of the Public Warrants as of June 30, 2021 is based on observable listed prices for such warrants. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.


	For The three
	Months Ended
	March 31, 2021
Class A Common stock subject to possible redemption
Numerator: Earnings allocable to Common stock subject to possible redemption
Income from investments held in Trust Account	$	8,434
Less: Company's portion available to be withdrawn to pay taxes		(8,434)
Net income attributable	$	—
Denominator: Weighted average Class A common stock subject to possible redemption
Basic and diluted weighted average shares outstanding		9,743,321
Basic and diluted net income per share	$	—

Non-Redeemable Common Stock
Numerator: Net Income minus Net Earnings allocable to Class A common stock subject to possible redemption
Net income	$	2,783,333
Net income allocable to Class A common stock subject to possible redemption		—
Non-redeemable net income	$	2,783,333
Denominator: weighted average Non-redeemable common stock
Basic and diluted weighted average shares outstanding, Non-redeemable common stock		3,968,490
Basic and diluted net loss per share, Non-redeemable common stock	$	0.70

Offering Costs Associated with the Initial Public Offering

Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A common stock were charged to stockholders’ equity upon the completion of the Initial Public Offering. Of the total offering costs of the Initial Public Offering, approximately $0.3 million is included in offering cost - derivative warrant liabilities in the unaudited condensed statements of operations and $6.5 million is included in stockholders’ equity.

13Class A common stock subject to possible redemption

~~Table~~The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within the control of ~~Contents~~the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. The Company’s Class A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2021, 9,716,668 shares of Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets. There were no Class A common stock issued and outstanding as of December 31, 2020.

~~Recent Accounting Pronouncements~~12

InTable August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of ~~the ASU did not impact the Company’s financial position, results of operations or cash flows.~~Contents

CA HEALTHCARE ACQUISITION CORP.

~~Management~~NOTES ~~does~~TO ~~not~~UNAUDITED ~~believe~~CONDENSED ~~that~~FINANCIAL ~~any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a material effect on the Company’s unaudited condensed financial statements.~~STATEMENTS

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2021, the Company had deferred tax assets of approximately $104,000 with a full valuation allowance against them.

~~Note~~ASC ~~4—Initial~~740 ~~Public~~prescribes ~~Offering~~a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021 or December 31, 2020. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. The Company’s currently taxable income primarily consists of interest and dividends earned and unrealized gains on investments held in the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible.

OnNo ~~January~~amounts ~~29,~~were ~~2021,~~accrued for the ~~Company~~payment ~~consummated~~of ~~its~~interest ~~Initial~~and ~~Public~~penalties ~~Offering~~as of ~~11,500,000~~June ~~Units~~30, ~~including~~2021 ~~1,500,000~~and ~~Over-Allotment~~December ~~Units~~31, ~~at $10~~2020.00 ~~per~~The ~~Unit,~~Company ~~generating~~is ~~gross~~currently ~~proceeds~~not aware of ~~$115.0~~any ~~million,~~issues ~~and~~under ~~incurring~~review ~~offering~~that ~~costs~~could ofresult ~~approximately~~in ~~$6.5~~significant ~~million~~payments, ofaccruals ~~which~~or ~~approximately~~material $4deviation from its position.0 ~~million~~The ~~was~~Company ~~for~~is ~~deferred~~subject ~~underwriting~~to ~~commissions~~income tax examinations by major taxing authorities since inception.

~~Each~~Net ~~Unit~~Income ~~consists of one share of Class A common stock, and one-half of one redeemable warrant~~ (~~each, a “Public Warrant”~~Loss). ~~Each~~Per ~~Public~~Share ~~Warrant entitles the holder to purchase one share~~ of ~~Class~~Common ~~A common stock at a price of $11.50 per share, subject to adjustment (see Note 7).~~Stock

Net income (loss) per common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 9,800,000 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

~~Note~~The ~~5—Related~~Company’s ~~Party~~unaudited ~~Transactions~~condensed statements of operations includes a presentation of income (loss) per common share for common shares subject to possible redemption in a manner similar to the two-class method of income (loss) per common share. Net income (loss) per common stock, basic and diluted, for Class A common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on investments held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of common stock subject to possible redemption outstanding since original issuance.

~~Founder~~Net ~~Shares~~income (loss) per share, basic and diluted, for non-redeemable common stock is calculated by dividing the net income (loss), adjusted for income or loss on investments held in the Trust Account attributable to common stock subject to possible redemption, by the weighted average number of non-redeemable common stock outstanding for the period.

OnNon-redeemable ~~October~~common ~~28,~~stock ~~2020,~~includes ~~the~~Founder ~~Sponsor~~Shares ~~purchased~~and ~~2,875,000~~non-redeemable shares of ~~the Company’s~~ Class BA common stock, ~~par~~as ~~value $0.0001 per share, (the “Founder Shares”) for an aggregate purchase price of $25,000, or approximately $0.009 per share. Of~~ these, ~~up to 375,000~~ shares ~~were~~do ~~subject~~not tohave ~~forfeiture~~any byredemption ~~the~~features. ~~Sponsor to the extent that the underwriters’ over~~Non-~~allotment~~redeemable ~~was~~common ~~not~~stock ~~exercised~~participates in ~~full, so that~~ the ~~initial~~income ~~stockholders~~or ~~would~~loss ~~own~~on ~~20.0%~~investments ofheld ~~the~~in ~~Company’s issued and outstanding shares after~~ the ~~Initial~~Trust ~~Public~~Account ~~Offering.~~based Onon ~~January 29, 2021, the underwriters fully exercised the over~~non-~~allotment~~redeemable ~~option;~~shares’ ~~thus,~~proportionate ~~these 375,000 Founder Shares were no longer subject to forfeiture~~interest.

The Company’s initial stockholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property.13

~~Private~~Table ~~Placement~~of ~~Warrants~~Contents

~~Simultaneously~~CA ~~with~~HEALTHCARE ~~the~~ACQUISITION ~~closing of the Initial Public Offering, the Company consummated the Private Placement of 4,050,000 Private Placement Warrants at a price of $1~~CORP.~~00 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $4.1 million.~~

14NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

~~Table~~The following table reflects the calculation of ~~Contents~~basic and diluted net income (loss) per common share:

Each Private Placement Warrant will be exercisable to purchase one share of Class A common stock at a price of $11.50 per share. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Placement Warrants.

Promissory Note — Related Party


			For The six
		For the three months	months ended
		ended June 30, 2021	June 30, 2021
Class A Common stock subject to possible redemption
Numerator: Earnings allocable to Common stock subject to possible redemption
Income from investments held in Trust Account	$	2,354	$	10,505
Less: Company's portion available to be withdrawn to pay taxes		(2,354)		(10,505)
Net income attributable	$	—	$	—
Denominator: Weighted average Class A common stock subject to possible redemption
Basic and diluted weighted average shares outstanding		10,049,964		9,925,703
Basic and diluted net income per share	$	—	$	—

Non-Redeemable Common Stock
Numerator: Net Income minus Net Earnings allocable to Class A common stock subject to possible redemption
Net loss	$	(3,369,989)	$	(586,656)
Net income allocable to Class A common stock subject to possible redemption		—		—
Non-redeemable net loss	$	(3,369,989)	$	(586,656)
Denominator: weighted average Non-redeemable common stock
Basic and diluted weighted average shares outstanding, Non-redeemable common stock		4,325,036		4,147,748
Basic and diluted net loss per share, Non-redeemable common stock	$	(0.78)	$	(0.14)

On October 28, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and was due on the earlier of March 31, 2021 or the completion of the Initial Public Offering. The Company borrowed approximately $134,000 under the terms of the Note. The loan balance of $134,000 was fully repaid on January 29, 2021.

~~Due~~Recent ToAccounting ~~Related Party~~Pronouncements

AsIn ofAugust ~~March 31~~2020, ~~2021~~the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, ~~there~~Debt—Debt iswith Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an ~~outstanding~~Entity’s ~~balance~~Own ofEquity $2(“ASU 2020-06”),~~275~~ ~~due~~which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the ~~Sponsor~~derivative ~~for~~scope exception, and it simplifies the diluted earnings per share calculation in certain ~~reimbursable~~areas. ~~expenses~~The ~~and~~Company ~~other~~adopted ~~expenses~~ASU ~~paid~~2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s ~~behalf.~~financial ~~The~~position, ~~balance~~results isof ~~non-interest~~operations ~~bearing~~or ~~and~~cash ~~payable upon demand~~flows.

~~Related~~Management ~~Party~~does ~~Loans~~not believe that any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a material effect on the Company’s unaudited condensed financial statements.

In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of notes may be converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $1.00 per Warrant. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of March 31, 2021, there were no Working Capital Loans outstanding.

Note 64—~~Commitments~~Initial ~~and~~Public ~~Contingencies~~Offering

~~Registration~~On ~~Rights~~January 29, 2021, the Company consummated its Initial Public Offering of 11,500,000 Units, including 1,500,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $115.0 million, and incurring offering costs of approximately $6.5 million, of which approximately $4.0 million was for deferred underwriting commissions.

~~The~~Each ~~holders~~Unit ofconsists ~~the Founder Shares, Private Placement Warrants and any Warrants that may be issued upon conversion~~ of ~~the~~one ~~Working~~share ~~Capital Loans (and any shares~~ of Class A common stock, ~~issuable upon the exercise of the Private Placement Warrants~~ and ~~warrants~~one-half ~~that may be issued upon conversion~~ of ~~Working~~one ~~Capital~~redeemable ~~Loans~~warrant ~~and~~(each, ~~upon conversion of the Founder Shares) were entitled to registration rights pursuant to~~ a ~~registration rights agreement signed upon the effective date of the Initial~~ “Public ~~Offering~~Warrant”). ~~The~~Each ~~holders~~Public ofWarrant ~~these~~entitles ~~securities~~the ~~were~~holder ~~entitled~~ to ~~make~~purchase upone toshare ~~three~~of ~~demands,~~Class ~~excluding~~A ~~short~~common ~~form~~stock ~~demands,~~at ~~that~~a ~~the~~price ~~Company~~of ~~register such securities~~$11.50 per ~~In addition~~share, ~~the~~subject ~~holders have certain “piggy-back” registration rights with respect~~ to ~~registration~~adjustment ~~statements~~(see ~~filed~~Note ~~subsequent to the consummation of a Business Combination~~7). The registration rights agreement will not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

~~Table of Contents~~14

~~Underwriting~~Table ~~Agreement~~of Contents

~~The~~CA ~~Company~~HEALTHCARE ~~granted~~ACQUISITION ~~the underwriters a 45-day option to purchase up to 1,500,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions~~CORP. ~~On January 29, 2021, the underwriters fully exercised the over-allotment option.~~

~~The~~NOTES ~~underwriters~~TO ~~were~~UNAUDITED ~~entitled~~CONDENSED toFINANCIAL a cash underwriting discount of 2.0% of the gross proceeds of the Initial Public Offering, or $2.3 million in the aggregate. In addition, the representative of the underwriters will be entitled to a deferred fee of 3.5% of the Initial Public Offering, or approximately $4.0 million in aggregate. The deferred fee will become payable to the representative of the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.STATEMENTS

Note 5—Related Party Transactions

~~Note~~Founder ~~7—Derivative Warrant Liabilities~~Shares

AsOn ofOctober ~~March~~28, 312020, ~~2021~~the Sponsor purchased 2,875,000 ~~there~~shares ~~were~~of 5the Company’s Class B common stock,~~750~~ par value $0.0001 per share, (the “Founder Shares”) for an aggregate purchase price of $25,000, ~~and~~or 4approximately $0.009 per share. Of these,~~050~~ up to 375,000 ~~Public~~shares ~~Warrants~~were subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment was not exercised in full, so that the initial stockholders would own 20.0% of the Company’s issued and ~~Private~~outstanding ~~Placement~~shares ~~Warrants~~after the Initial Public Offering. On January 29, ~~respectively~~2021, ~~outstanding~~the underwriters fully exercised the over-allotment option; thus, these 375,000 Founder Shares were no longer subject to forfeiture.

The ~~Public~~Company’s ~~Warrants~~initial ~~will~~stockholders ~~become~~agreed ~~exercisable~~not onto ~~the~~transfer, ~~later~~assign ~~of (a) 30 days after the consummation of a Business Combination~~ or ~~(b)~~sell 12any ~~months from the closing~~ of ~~the~~their ~~Initial~~Founder ~~Public~~Shares ~~Offering,~~until ~~provided in each case that~~ the ~~Company~~earlier ~~has~~to anoccur ~~effective registration statement under the Securities Act covering the shares~~ of: ~~Class~~ (A) ~~common~~one ~~stock~~year ~~issuable~~after ~~upon~~the ~~exercise~~completion of ~~the warrants and~~ a ~~current~~Business ~~prospectus~~Combination ~~relating~~or ~~to them is available~~ (orB) ~~the~~subsequent ~~Company permits holders~~ to ~~exercise their warrants on a cashless basis under certain circumstances). The Company agreed that as soon as practicable, but in no event later than 15 business days after~~ the ~~closing of the~~ initial Business Combination, it(x) ~~will~~if ~~its best efforts to file with~~ the ~~SEC~~last asale ~~registration~~price ~~statement~~of ~~covering~~ the ~~shares of~~ Class A common stock ~~issuable~~equals ~~upon~~or ~~exercise~~exceeds of$12.00 ~~the~~per ~~warrants,~~share to(as ~~cause~~adjusted ~~such~~for ~~registration~~stock ~~statement~~splits, ~~to become effective and to maintain a current prospectus relating to those shares of Class A common~~ stock ~~until~~dividends, ~~the~~reorganizations, ~~warrants~~recapitalizations ~~expire~~and ~~or are redeemed. If a registration statement covering~~ the ~~shares~~like) offor ~~Class~~any A20 ~~common~~trading ~~stock~~days ~~issuable~~within ~~upon~~any ~~exercise~~30-trading ofday ~~the~~period ~~warrants~~commencing isat ~~not~~least ~~effective~~150 days ~~by the 60th business day~~ after the ~~closing of the~~ initial Business Combination, ~~the~~or ~~warrant~~(y) ~~holders~~the ~~may,~~date ~~until~~on ~~such~~which ~~time as there is an effective registration statement and during any period when~~ the Company ~~will~~completes ~~have~~a ~~failed~~liquidation, tomerger, ~~maintain~~capital anstock ~~effective registration statement~~exchange, ~~exercise~~reorganization ~~warrants~~or onother asimilar ~~“cashless~~transaction ~~basis”~~that results in ~~accordance~~all ~~with Section 3(a)(9)~~ of the ~~Securities~~stockholders ~~Act~~having orthe ~~another~~right ~~exemption.~~to Ifexchange ~~that~~their ~~exemption,~~shares orof ~~another~~common ~~exemption,~~stock isfor ~~not available~~cash, ~~holders~~securities ~~will~~or ~~not~~other ~~be able to exercise their warrants on a cashless basis~~property.

~~The~~Private ~~warrants~~Placement have an exercise price of $11.50 per share, subject to adjustments, and will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.Warrants

16Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 4,050,000 Private Placement Warrants to the Sponsor at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $4.1 million.

~~Table~~Each Private Placement Warrant will be exercisable to purchase one share of ~~Contents~~Class A common stock at a price of $11.50 per share, subject to adjustment. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Placement Warrants.

~~Additionally,~~Promissory inNote — noRelated event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.Party

~~Once~~On October 28, 2020, the ~~warrants~~Sponsor ~~become~~agreed ~~exercisable,~~to loan the Company ~~may~~an ~~redeem~~aggregate of up to $300,000 to cover expenses related to the ~~outstanding~~Initial ~~warrants~~Public Offering pursuant to a promissory note (~~excluding~~the “Note”). This loan was non-interest bearing and was due on the ~~Private~~earlier ~~Placement~~of ~~Warrants):~~March 31, 2021 or the completion of the Initial Public Offering. The Company borrowed approximately $134,000 under the terms of the Note. The loan balance of $134,000 was fully repaid on January 29, 2021.

~~● in~~Due ~~whole~~To ~~and~~Related ~~not in part;~~Party

~~● at~~As aof ~~price~~June 30, 2021, there is an outstanding balance of $02,275 due to the Sponsor for certain reimbursable expenses and other expenses paid on the Company’s behalf.01 ~~per~~The ~~warrant;~~balance is non-interest bearing and payable upon demand.

~~● upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and~~

● if, and only if, the last sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.15

~~The~~Table ~~Company will not redeem the warrants unless a registration statement under the Securities Act covering the shares~~ of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants become redeemable by the Company, it may not exercise its redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification.Contents

~~The~~CA ~~Private~~HEALTHCARE ~~Placement~~ACQUISITION Warrants will be identical to the Public Warrants underlying the Units being sold in the Initial Public Offering, except that the Private Placement Warrants will, and the common shares issuable upon the exercise of the Private Placement Warrants will not, be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptionsCORP. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and will be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

~~Note~~Related ~~8—Stockholders’~~Party ~~Equity~~Loans

~~Preferred~~In ~~Stock~~order —to ~~The~~finance transaction costs in connection with a Business Combination, the Company’s isSponsor, ~~authorized~~an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, ~~issue~~loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of notes may be converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $1.00 per Warrant. In the event that a Business Combination does not close,~~000~~ the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing,~~000~~ ~~shares~~the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $01.~~0001~~5 ~~par~~million ~~value~~of ~~preferred~~such ~~stock~~Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of ~~March~~June 3130, 2021 and December 31, 2020, there were no ~~preferred~~Working ~~shares~~Capital ~~issued~~Loans or outstanding.

Class A Common Stock — The Company is authorized to issue up to 100,000,000 shares of Class A, $0.0001 par value common stock. Holders of the Company’s Class A common stock are entitled to one vote for each share. As of March 31, 2021, there were 1,446,333 shares of Class A common stock issued and outstanding, excluding 10,053,667 shares of Class A common stock subject to possible redemption.

17Note 6—Commitments and Contingencies

~~Table~~Registration ~~of Contents~~Rights

The holders of the Founder Shares, Private Placement Warrants and any Warrants that may be issued upon conversion of the Working Capital Loans (and any shares of Class BA ~~Common~~common ~~Stock~~stock —issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the Initial Public Offering. The ~~Company~~holders isof ~~authorized~~these securities were entitled to ~~issue~~make up to 10three demands,~~000~~ excluding short form demands,~~000~~ ~~shares~~that ofthe ~~Class~~Company Bregister such securities. In addition, $0the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination.~~0001~~ ~~par~~The ~~value~~registration ~~common~~rights ~~stock~~agreement will not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. AsThe ofCompany ~~March~~will ~~31,~~bear ~~2021,~~the ~~there~~expenses ~~were~~incurred ~~2,875,000~~in ~~shares~~connection ofwith ~~Class~~the Bfiling ~~common~~of ~~stock~~any ~~issued~~such ~~and~~registration ~~outstanding~~statements.

~~Holders~~Underwriting of the Company’s Class B common stock are entitled to one vote for each share. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Business Combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of the Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).Agreement

The Company granted the underwriters a 45-day option to purchase up to 1,500,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On January 29, 2021, the underwriters fully exercised the over-allotment option.

~~Note~~The ~~9—Fair~~underwriters ~~Value~~were ~~Measurements~~entitled to a cash underwriting discount of 2.0% of the gross proceeds of the Initial Public Offering, or $2.3 million in the aggregate. In addition, the representative of the underwriters will be entitled to a deferred fee of 3.5% of the Initial Public Offering, or approximately $4.0 million in aggregate. The deferred fee will become payable to the representative of the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

The following tables presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 by level within the fair value hierarchy:


	Quoted Prices in Active		Significant Other		Significant Other
	Markets		Observable Inputs		Unobservable Inputs
Description	(Level 1)		(Level 2)		(Level 3)
Assets:
U.S. Treasury Securities	$	115,009,648	$	—	$	—

Liabilities:
Derivative warrant liabilities	$	3,047,500	$	—	$	3,483,000

Note 7—Derivative Warrant Liabilities

As of June 30, 2021, there were 5,750,000 and 4,050,000 Public Warrants and Private Placement Warrants, respectively, outstanding. There were no warrants outstanding as of December 31, 2020.

Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the three months ended March 31, 2021 was approximately $3 million, when the Public Warrants were separately listed and traded.16

~~Level~~Table 1 instruments include investments in mutual funds invested in government securities and the Public Warrants. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of ~~its investments.~~Contents

~~The~~CA ~~fair~~HEALTHCARE ~~value~~ACQUISITION of the Public Warrants issued in connection with the Public Offering were initially measured at fair value using a Monte Carlo simulation model and subsequently are based on the listed market price of such warrants, a Level 1 measurement since March 9, 2021CORP. The fair value of the Private Placement Warrants have been measured at fair value using a Black-Scholes simulation. For the three months ended March 31, 2021, the Company recognized a gain to the statement of operations resulting from a decrease in the fair value of liabilities of approximately $3.4 million presented as change in fair value of derivative warrant liabilities on the accompanying unaudited condensed statement of operations.

~~The~~NOTES ~~estimated~~TO ~~fair~~UNAUDITED ~~value~~CONDENSED ofFINANCIAL the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, is determined using Level 3 inputs. Inherent in a Black-Scholes simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.STATEMENTS

18The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under certain circumstances). The Company agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, it will its best efforts to file with the SEC a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, the warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

~~Table~~The warrants have an exercise price of ~~Contents~~$11.50 per share, subject to adjustment, and will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The ~~following~~exercise ~~table~~price ~~provides~~and ~~quantitative~~number ~~information~~of ~~regarding~~common ~~Level~~shares 3issuable ~~fair~~upon ~~value~~exercise ~~measurements~~of ~~inputs~~the atPublic Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their ~~measurement~~warrants, ~~dates:~~nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.


	As of January 29, 2021						As of March 31, 2021
	Public			Private			Private
Volatility		20.0	%		20.0	%		17.5	%
Stock price	$	9.76		$	9.76		$	9.67
Expected term to Business Combination		5.4			5.4			5.25
Risk-free rate		0.50	%		0.50	%		1.00	%
Dividend yield		0.0	%		0.0	%		0.0	%

Once the warrants become exercisable, the Company may redeem the outstanding warrants (excluding the Private Placement Warrants):

● in whole and not in part;

~~The following table presents the changes in the fair value of warrant liabilities:~~17

Table of Contents


	Private Placement		Public		Warrant Liabilities
Fair value as of January 1, 2021	$	—	$	—	$	—
Initial measurement on January 29, 2021		4,050,000		5,807,500		9,857,500
Change in valuation inputs or other assumptions		(567,000)		(2,760,000)		(3,327,000)
Fair value as of March 31, 2021	$	3,483,000	$	3,047,500	$	6,530,500

CA HEALTHCARE ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

● at a price of $0.01 per warrant;

● upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and

~~Note~~● if, ~~10—Subsequent~~and ~~Events~~only if, the last sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

The Company ~~evaluated~~will ~~subsequent~~not ~~events~~redeem ~~and~~the ~~transactions~~warrants ~~that~~unless ~~occurred~~a ~~after~~registration statement under the ~~balance~~Securities ~~sheet~~Act ~~date~~covering upthe shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the ~~date~~30-day ~~that~~redemption period, except if the ~~unaudited~~warrants ~~condensed~~may ~~financial~~be ~~statements~~exercised ~~were~~on ~~issued~~a cashless basis and such cashless exercise is exempt from registration under the Securities Act. ~~Based~~If ~~upon~~and ~~this~~when ~~review,~~the ~~except~~warrants asbecome ~~noted~~redeemable ~~below,~~by the Company, ~~did~~it may not ~~identify~~exercise ~~any~~its ~~subsequent~~redemption ~~events~~right ~~that~~if ~~would~~the ~~have~~issuance ~~required~~of ~~adjustment~~shares of common stock upon exercise of the warrants is not exempt from registration or ~~disclosure~~qualification inunder applicable state blue sky laws or the ~~unaudited~~Company ~~condensed~~is ~~financial~~unable ~~statements~~to effect such registration or qualification.

The Private Placement Warrants will be identical to the Public Warrants underlying the Units being sold in the Initial Public Offering, except that the Private Placement Warrants will, and the common shares issuable upon the exercise of the Private Placement Warrants will not, be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and will be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

On April 6, 2021, the Company, LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“LumiraDx”) and LumiraDx Merger Sub, Inc., a newly formed Delaware corporation and wholly owned subsidiary of LumiraDx (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) that, among other things, provides for Merger Sub to be merged with and into the Company with the Company being the surviving corporation in the merger (the “Merger”). As a result of and upon consummation of the Merger, the Company will become a wholly owned subsidiary of LumiraDx, with security holders of the Company becoming security holders of LumiraDx. The Merger Agreement contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Merger and the other transactions contemplated thereby. The consummation of the transactions contemplated by the Merger Agreement is subject to the satisfaction (or waiver) of the conditions set forth therein.

Note 8—Stockholders’ Equity

Preferred Stock — The Company is authorized to issue 1,000,000 shares of $0.0001 par value preferred stock. As of June 30, 2021, there were no preferred shares issued or outstanding.

Class A Common Stock — The Company is authorized to issue up to 100,000,000 shares of Class A, $0.0001 par value common stock. Holders of the Company’s Class A common stock are entitled to one vote for each share. As of June 30, 2021, there were 1,783,332 shares of Class A common stock issued and outstanding, excluding 9,716,668 shares of Class A common stock subject to possible redemption. There were no Class A common stock issued and outstanding as of December 31, 2020.

Class B Common Stock — The Company is authorized to issue up to 10,000,000 shares of Class B, $0.0001 par value common stock. As of June 30, 2021 and December 31, 2020, there were 2,875,000 shares of Class B common stock issued and outstanding.

1918

Table of Contents

CA HEALTHCARE ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Holders of the Company’s Class B common stock are entitled to one vote for each share. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Business Combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon the completion of the Initial Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company).

Note 9—Fair Value Measurements

The following tables presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2021 by level within the fair value hierarchy:


	Quoted Prices in Active		Significant Other		Significant Other
	Markets		Observable Inputs		Unobservable Inputs
Description	(Level 1)		(Level 2)		(Level 3)
Assets:
Investments held in Trust Account	$	115,012,434	$	—	$	—
Liabilities:
Derivative warrant liabilities - Public Warrants	$	5,577,500	$	—	$	—
Derivative warrant liabilities - Private Placement Warrants	$	—	$	—	$	4,009,500

Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the six months ended June 30, 2021 was approximately $3.0 million, when the Public Warrants were separately listed and traded.

Level 1 instruments include investments in mutual funds invested in government securities and the Public Warrants. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

The fair value of the Public Warrants issued in connection with the Public Offering were initially measured at fair value using a Monte Carlo simulation model and subsequently are based on the listed market price of such warrants, a Level 1 measurement since March 9, 2021. The fair value of the Private Placement Warrants have been measured at fair value using a Black-Scholes simulation. For the three months ended June 30, 2021, the Company recognized a loss to the statements of operations resulting from an increase in the fair value of liabilities of approximately $3.1 million presented as change in fair value of derivative warrant liabilities on the accompanying unaudited condensed statements of operations. For the six months ended June 30, 2021, the Company recognized a gain to the unaudited condensed statements of operations resulting from a decrease in the fair value of liabilities of approximately $271,000 presented as change in fair value of derivative warrant liabilities on the accompanying unaudited condensed statement of operations.

Table of Contents

CA HEALTHCARE ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

The estimated fair value of the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, is determined using Level 3 inputs. Inherent in a Black-Scholes simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates:


	As of January 29, 2021						As of March 31, 2021			As of June 30, 2021
	Public			Private			Private			Private
Volatility		20.0	%		20.0	%		17.5	%		18.0	%
Stock price	$	9.76		$	9.76		$	9.67		$	9.88
Expected term to Business Combination		5.40			5.40			5.25			5.00
Risk-free rate		0.50	%		0.50	%		1.00	%		0.90	%
Dividend yield		0.0	%		0.0	%		0.0	%		0.0	%

The following table presents the changes in the fair value of warrant liabilities:


	Private Placement		Public		Warrant Liabilities
Fair value as of January 1, 2021	$	—	$	—	$	—
Initial measurement on January 29, 2021		4,050,000		5,807,500		9,857,500
Change in fair value of derivative warrant liabilities		(567,000)		(2,760,000)		(3,327,000)
Fair value as of March 31, 2021		3,483,000		3,047,500		6,530,500
Change in fair value of derivative warrant liabilities		526,500		2,530,000		3,056,500
Fair value as of June 30, 2021	$	4,009,500	$	5,577,500	$	9,587,000

Note 10—Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “our,” “us” or “we” refer to CA Healthcare Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form 10-Q. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.

Overview

We are a blank check company incorporated in Delaware on October 7, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). Our sponsor is CA Healthcare Sponsor LLC (“Sponsor”).

The registration statement for our Initial Public Offering (“Initial Public Offering”) was declared effective by the SEC on January 26, 2021. On January 29, 2021, we consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), including 1,500,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $115.0 million, and incurring offering costs of approximately $6.5 million, of which approximately $4.0 million was for deferred underwriting commissions.

Simultaneously with the closing of the Initial Public Offering, we consummated the private placement (“Private Placement”) to our Sponsor of 4,050,000 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant to our Sponsor, generating proceeds of approximately $4.1 million.

Upon the closing of the Initial Public Offering and the Private Placement, $115.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”) in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less, or in any money market funds meeting certain conditions of Rule 2a-7 of the Investment Company Act, which invest only in direct U.S, government treasury obligations until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to our stockholders, as described below.

2021

Table of Contents

If we are unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or January 29, 2023 (the “Combination Period”), we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and our board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirement of applicable law. The representative of the underwriters agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event we do not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

Results of Operations

Our entire activity from October 7, 2020 (inception) through ~~March 31~~June 30, 2021, was in preparation for an Initial Public Offering, and since our Initial Public Offering, our activity has been limited to the search for a prospective initial Business Combination. We will not generate any operating revenues until the closing and completion of our initial Business Combination. We generate non-operating income in the form of investment income from our investments held in the Trust Account. We expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended ~~March 31~~June 30, 2021, we had a net ~~income~~loss of approximately $23.84 million, which consisted of approximately $3~~.3 million of change in fair value of derivative warrant liabilities and approximately $10~~,000 of income from investments held in Trust Account, ~~partially~~ offset by approximately $~~144,000~~3.1 million of ~~general~~change ~~and~~in ~~administrative~~fair ~~expenses~~value of derivative warrant liabilities, approximately $49266,000 of ~~franchise~~general ~~tax~~and ~~expense~~administrative expenses, and approximately $~~361~~50,000 of ~~financing~~franchise ~~costs –~~tax ~~derivative warrant liabilities~~expense.

For the six months ended June 30, 2021, we had a net loss of approximately $579,000, which consisted of approximately $271,000 of change in fair value of derivative warrant liabilities and approximately $12,000 of income from investments held in Trust Account, offset by $403,000 of general and administrative expenses, approximately $99,000 of franchise tax expense, and approximately $361,000 of offering costs - derivative warrant liabilities.

Liquidity and Capital Resources

As of ~~March 31~~June 30, 2021, we had approximately $~~847~~624,000 in cash and working capital of approximately $1766,000.~~1 million.~~

Our liquidity needs tothrough ~~date~~June ~~have~~30, ~~been~~2021 and prior were satisfied through a cash payment of $25,000 from our Sponsor to purchase the Founder Shares (as defined below), a loan under a promissory note from our Sponsor of approximately $134,000, and the net proceeds from the consummation of the Private Placement not held in the Trust Account. We fully repaid the loan on January 29, 2021. In addition, in order to finance transaction costs in connection with an Initial Business Combination, our officers, directors and initial stockholders may, but are not obligated to, provide us Working Capital Loans. As of ~~March 31~~June 30, 2021 and December 31, 2020, there were no amounts outstanding under any Working Capital Loans.

Based on the foregoing, management believes that we will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

Table of Contents

Contractual Obligations

We do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities.

Table of Contents

Critical Accounting Policies

This management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these unaudited condensed financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Investments Held in the Trust Account

~~Our~~The Company’s portfolio of investments ~~held in the Trust Account~~ is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. ~~Our~~When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance ~~sheet~~sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these ~~investments~~securities ~~are~~is included in income from investments held in Trust Account in the accompanying unaudited condensed ~~statement~~statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

Class A Common Stock Subject to Possible Redemption

We account for our Class A common stock subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 480 “Distinguishing Liabilities from Equity.” Shares of Class A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Shares of conditionally redeemable Class A common stock (including Class A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, shares of Class A common stock are classified as stockholders’ equity. Our Class A common stock features certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of ~~March 31~~June 30, 2021, a total of 109,~~053~~716,~~667~~668 shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of our balance sheet. There were no Class A common stock issued and outstanding as of December 31, 2020.

Derivative warrant liabilities

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The 5,750,000 warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the 4,050,000 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering were initially measured at fair value using a Monte Carlo simulation model and subsequently at their listed trading price. The fair value of the Private Warrants were initially and subsequently measured at fair value using a Black-Scholes simulation.23

Table of Contents

Offering Costs Associated with the Initial Public Offering

Net Income (Loss) Per Share of Common Stock

Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. ~~The~~We ~~Company~~have ~~has~~ not considered the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase an aggregate of 9,800,000 shares of our common stock in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

We apply the two-class method in calculating earnings per share. Net income (loss) per common ~~share~~stock, basic and diluted for Class A common stock subject to possible redemption is calculated by dividing the income earned on the Trust Account, net of applicable taxes, if any, by the weighted average number of shares of Class A common stock subject to possible redemption outstanding for the period. Net income (loss) per common ~~share~~stock, basic and diluted for non-redeemable common stock is calculated by dividing net loss less income attributable to Class A shares common stock subject to possible redemption, by the weighted average number of shares of non-redeemable common stock outstanding for the period presented.

Recent Accounting Pronouncements

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. We adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact our financial position, results of operations or cash flows.

Our management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.

Off-Balance Sheet Arrangements

As of ~~March~~June 3130, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

Table of Contents

JOBS Act

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Table of Contents

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of ~~March~~June 3130, 2021. Based upon that evaluation, our principal executive officer and principal financial and accounting officer concluded that our disclosure controls and procedures were not effective as of ~~March~~June 3130, 2021, due to issues related to the accounting for the Company’s warrants, as described below.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

~~There~~Other than as discussed herein, there was no change in our internal control over financial reporting that occurred during the fiscal quarter ended ~~March~~June 3130, 2021 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC (the “SEC Staff”) issued a statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity, in accordance with Accounting Standards Codification 815-40, Derivatives and Hedging: Contracts in an Entities Own Equity (“ASC 815-40”). Since issuance on January 29, 2021, the Company’s warrants, which includes (i) 5,750,000 redeemable warrants included as a part of the Units issued by the Company in the Initial Public Offering (the “Public Warrants”) and (ii) 4,050,000 Private Placement Warrants (together with the Public Warrants, the “Warrants”), were accounted for as equity within the Company’s financial statements.25

Table of Contents

After consideration of the guidance in the SEC Staff Statement, the Company concluded that the Warrants should be accounted for as a liability and measured at fair value with changes in fair value for each period reported in the Company’s statement of operations. The Company has reflected this revision as a correction of an error in the Company’s financial statements as of and for the three month period ended March 31, 2021.

In light of the revision to the classification of the Warrants as liabilities in our financial statements, including our January 29, 2021 audited balance sheet, as described in Note 2 of the accompanying condensed financial statements, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

In addition to the risk factors previously disclosed in the Company’s final prospectus for the Initial Public Offering as filed with the SEC on January 27, 2021, the Company notes the following additional risk factor:

Our warrants are accounted for as liabilities and the changes in value of our warrants could have a material effect on our financial results.

On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the “SEC Statement”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement governing our warrants.

As a result, included on our balance sheet as of March 31, 2021 contained ~~elsewhere~~ in ~~this~~our March 31, 2021 quarterly report in Form 10-Q are derivative liabilities related to embedded features contained within our warrants. Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”) provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statements of operations. As a result of the recurring fair value measurement, our financial statements and results of operations may fluctuate quarterly based on factors which are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our warrants each reporting period and that the amount of such gains or losses could be material.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities

Unregistered Sales of Equity Securities

On October 28, 2020, our Sponsor purchased 2,875,000 shares of the Company’s Class B common stock, par value $0.0001 per share, (the “Founder Shares”) for an aggregate purchase price of $25,000, or approximately $0.009 per share. Of these, up to 375,000 shares were subject to forfeiture by our Sponsor to the extent that the underwriters’ over-allotment was not exercised in full, so that the initial stockholders would own 20.0% of the Company’s issued and outstanding shares after the Initial Public Offering. On January 29, 2021, the underwriters fully exercised the over-allotment option; thus, these 375,000 Founder Shares were no longer subject to forfeiture.

Table of Contents

On January 29, 2021, we consummated the Private Placement of 4,050,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant to our Sponsor, generating proceeds of approximately $4.1 million. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

No underwriting discounts or commissions were paid with respect to such sales.

Use of Proceeds

On January 29, 2021, we consummated the Initial Public Offering of 11,500,000 Units, including 1,500,000 additional Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $115.0 million, and incurring offering costs of approximately $6.5 million, of which approximately $4.0 million was for deferred underwriting commissions.

After deducting the underwriting discounts and commissions (excluding the deferred portion, which amount will be payable upon consummation of the Initial Business Combination, if consummated) and the other offering costs incurred, $115.0 million of the net proceeds from our Initial Public Offering, sale of the Over-Allotment Units and certain of the proceeds from the private placement of the Private Placement Warrants (or $10.00 per Unit sold in the Initial Public Offering) was placed in the Trust Account. The net proceeds of the Initial Public Offering, sale of the Over-Allotment Units and certain proceeds from the sale of the Private Placement Warrants are held in the Trust Account and invested as described elsewhere in this Quarterly Report on Form 10-Q.

There has been no material change in the planned use of the proceeds from the Initial Public Offering and Private Placement as is described in the Company’s final prospectus related to the Initial Public Offering.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits.


ExhibitNumber		Description

31.1		Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

Table of Contents


101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

2728

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this ~~24th~~2nd day of ~~May~~August 2021.


	CA HEALTHCARE ACQUISITION CORP.

	By:	/s/ Larry J. Neiterman
	Name:	Larry J. Neiterman
	Title:	Chief Executive Officer

Filing Compare · CA Healthcare Acquisition Corp.